WuXi Biologics Receives Esteemed CDMO Leadership Award for Ninth Straight Year

WuXi Biologics Honored with CDMO Leadership Awards for the Ninth Consecutive Year

WuXi Biologics, known as "WuXi Bio," has once again made headlines by being awarded the prestigious title of "Biologics CDMO of the Year" in the 2026 CDMO Leadership Awards. This marks the ninth consecutive year that WuXi Biologics has triumphed in this category, underscoring the company’s unyielding dedication to excellence in contract research, development, and manufacturing in the biologics sector.

The accolades from the CDMO Leadership Awards extend beyond the primary title. WuXi has been recognized in multiple categories for its exceptional capabilities within the large CDMO biologics sector, including accolades for "Best Scaling Support," "Best Analytical Services," "Best Overall Staff," and "Best Project Management." This recognition highlights WuXi Biologics’ commitment to advancing integrated technology platforms designed to expedite the discovery, development, and manufacturing of biologics.

Dr. Chris Chen, the CEO of WuXi Biologics, expressed pride in the company’s accomplishments, stating, "We are honored to receive the CDMO Leadership Award for the ninth consecutive year. This recognition reflects the continued trust of our global partners and the dedication of our more than 13,000 employees worldwide." Dr. Chen emphasized the importance of integrated technology platforms, manufacturing excellence, and digital innovation in WuXi Biologics’ operations.

As of the end of 2025, WuXi Biologics supports an impressive portfolio of 945 integrated projects, positioning itself as a prominent player in the biologics manufacturing space. The vast majority of these projects involve complex modalities, including bispecific or multispecific antibodies and antibody-drug conjugates (ADCs). WuXi’s technological advancements have drastically reduced the timelines needed for various phases of development: the average time from DNA to Investigational New Drug (IND) submission is now just 6 months, and from IND to Biologics License Application (BLA) completion is 15 months. These timelines significantly outperform the industry averages of 10-12 months and 24-36 months, respectively.

Relevant to its manufacturing capabilities, WuXi Biologics employs a holistic strategy that combines scalable and agile manufacturing solutions to meet the changing demands of the global market. A cutting-edge approach includes the use of large-volume single-use bioreactors (SUBs) with capacities of 2,000 L, 4,000 L, and even up to 5,000 L. Additionally, the combination of these SUBs allows for large-scale manufacturing volumes reaching up to 16,000 L. Emerging processes, such as WuXiUP™ and WuXiUI™, are significant for increasing productivity and efficiency in bioprocessing.

WuXia™ TrueSite, WuXi's next-generation cell line platform, has proven successful in achieving average monoclonal antibody (mAb) titers exceeding 8.0 g/L, showcasing remarkable stability across multiple generations.

Notably, WuXi Biologics has consistently achieved a 100% success rate in process performance qualification (PPQ) campaigns and has successfully delivered over 350 large-scale batches since 2017, each with capacities ranging from 6,000 L to 16,000 L. The company’s impressive track record is bolstered by its strong global quality system, evidenced by passing 46 regulatory inspections, including 22 by the FDA and EMA. WuXi Biologics also holds a remarkable record with a 100% success rate for FDA Pre-License Inspections (PLI).

At present, the company operates 15 GMP-certified facilities worldwide, possessing 136 approved facility licenses and achieving a 100% success rate in GMP inspections. This impeccable quality and compliance infrastructure forms a significant aspect of the trust bestowed by their global clientele.

In addition to traditional manufacturing approaches, WuXi Biologics is at the forefront of introducing digital innovation to the biologics research and development landscape. The integration of digital solutions across its operations enhances efficiency, data integrity, and product quality. Leveraging tools like Electronic Batch Records (EBR) has helped drive productivity gains of approximately 40% and improved efficiency by around 20% through advanced planning systems. Furthermore, the introduction of the innovative digital twin platform, PatroLab™, marks a substantial advancement in optimizing process performance while minimizing risks.

Fueled by its steadfast commitment to sustainability, WuXi Biologics aspires to leverage green technology innovations, offering end-to-end solutions that align with environmental, social, and governance standards. The company actively partners with stakeholders to foster positive impacts across its operational and community ecosystems.

With its eyes firmly set on the future, WuXi Biologics continues to push the boundaries of biologics innovation. To learn more, visit WuXi Biologics.